ELGEKA S.A. would like to notify the investing public that on Wednesday the 30th of December 2009, a contract was signed between its subsidiary company by a 91.34%, "SAMBROOK PHARMACEUTICALS S.A." and the company under the name "SAMBROOK MED PHARMACEUTICAL S.A." and the distinctive title "SAMBROOK MED S.A." a fully owned subsidiary of the company "ALAPIS S.A." for the transfer from the first company to the second of the business sector related to the trade of generic drugs of the pharmaceutical company "Sandoz", which has high brand awareness in the Greek market.
The above mentioned contract dictates a transfer of assets from "SAMBROOK PHARMACEUTICALS S.A." of a total value of 1.423 thousand euro and liabilities, more specifically a bank loan of 1.500 thousand euro. The buyer, "SAMBROOK MED S.A.", has undertaken the responsibility to settle this loan.
The total price related to the transfer of the business sector from "SAMBROOK PHARMACEUTICALS S.A." to "SAMBROOK MED S.A." amounted to 75 thousand euro.